TRAJAN GROUP HOLDINGS LIMITED (TRJ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TRJ - TRAJAN GROUP HOLDINGS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 3.94
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.15

18 Apr
2024

-0.080

OPEN

$1.18

-6.50%

HIGH

$1.19

11,078

LOW

$1.15

TARGET
$2.20 91.3% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
TRJ: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx N/A 3.1 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 35.8 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 20192020202120222023
EPS Basic xxxxxxxxxxxx1.2
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx162.2 M
Book Value Per Share xxxxxxxxxxxx85.2
Net Operating Cash Flow xxxxxxxxxxxx9.6 M
Net Profit Margin xxxxxxxxxxxx1.16 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20192020202120222023
Return on Capital Employed xxxxxxxxxxxx1.54 %
Return on Invested Capital xxxxxxxxxxxx1.24 %
Return on Assets xxxxxxxxxxxx0.87 %
Return on Equity xxxxxxxxxxxx1.54 %
Return on Total Capital xxxxxxxxxxxx5.46 %
Free Cash Flow ex dividends xxxxxxxxxxxx1.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20192020202120222023
Short-Term Debt xxxxxxxxxxxx12 M
Long Term Debt xxxxxxxxxxxx50 M
Total Debt xxxxxxxxxxxx61 M
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx11 M
Price To Book Value xxxxxxxxxxxx2.13

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20192020202120222023
Capex xxxxxxxxxxxx8.6 M
Capex % of Sales xxxxxxxxxxxx5.27 %
Cost of Goods Sold xxxxxxxxxxxx139 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

28/02/2024

1

Buy

$2.20

91.30%

Consistent customer destocking weighed on 1H results for Trajan Group, explains Ord Minnett, though customer demand rebounded in the latter part of the period.

Normalised core earnings (EBITDA) of $6.9m fell short of the broker's $12.9m estimate, owing to the softer 1H revenue.

While margins for the half were softer on those lower revenues, management expects a material increase in both revenue and earnings in the 2H after delivering upon the around $4m backlog, and after an easing in customer destocking.

Guidance is for FY24 revenue of between $163-167m, and normalised core EBITDA in the range of $22.3-23.7m.

The Buy rating is unchanged, but the target eases to $2.20 from $2.35.

FORECAST
Ord Minnett forecasts a full year FY24 dividend of 0.00 cents and EPS of 3.10 cents.
Ord Minnett forecasts a full year FY25 dividend of 0.00 cents and EPS of 6.50 cents.
Access Stockbroker Research History >

TRJ STOCK CHART

FNArena News on TRJ

1
Australian Broker Call *Extra* Edition – Mar 12, 2024

Mar 12 2024 - Daily Market Reports
2
FNArena Corporate Results Monitor – 28-02-2024

Feb 28 2024 - Australia
3
Australian Broker Call *Extra* Edition – Oct 10, 2023

Oct 10 2023 - Daily Market Reports
4
FNArena Corporate Results Monitor – 30-08-2023

Aug 30 2023 - Australia
5
Australian Broker Call *Extra* Edition – Jul 24, 2023

Jul 24 2023 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
2
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
3
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
4
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps
5
ResMed Recovery Turns Into Hollywood Script

Jan 31 2024 - Australia
6
ResMed Makes A Comeback

Jan 29 2024 - Australia
7
ResMed: The Recovery Has Begun

Jan 23 2024 - Technicals
8
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
9
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
10
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps